219 related articles for article (PubMed ID: 38030626)
1. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
[TBL] [Abstract][Full Text] [Related]
2. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
4. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities.
Krais JJ; Glass DJ; Chudoba I; Wang Y; Feng W; Simpson D; Patel P; Liu Z; Neumann-Domer R; Betsch RG; Bernhardy AJ; Bradbury AM; Conger J; Yueh WT; Nacson J; Pomerantz RT; Gupta GP; Testa JR; Johnson N
Nat Commun; 2023 Nov; 14(1):7714. PubMed ID: 38001070
[TBL] [Abstract][Full Text] [Related]
5. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis.
Gelot C; Kovacs MT; Miron S; Mylne E; Haan A; Boeffard-Dosierre L; Ghouil R; Popova T; Dingli F; Loew D; Guirouilh-Barbat J; Del Nery E; Zinn-Justin S; Ceccaldi R
Nature; 2023 Sep; 621(7978):415-422. PubMed ID: 37674080
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.
Fried W; Tyagi M; Minakhin L; Chandramouly G; Tredinnick T; Ramanjulu M; Auerbacher W; Calbert M; Rusanov T; Hoang T; Borisonnik N; Betsch R; Krais JJ; Wang Y; Vekariya UM; Gordon J; Morton G; Kent T; Skorski T; Johnson N; Childers W; Chen XS; Pomerantz RT
Nat Commun; 2024 Apr; 15(1):2862. PubMed ID: 38580648
[TBL] [Abstract][Full Text] [Related]
8. POLθ prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2/RAD51 by filling lagging-strand gaps.
Mann A; Ramirez-Otero MA; De Antoni A; Hanthi YW; Sannino V; Baldi G; Falbo L; Schrempf A; Bernardo S; Loizou J; Costanzo V
Mol Cell; 2022 Nov; 82(22):4218-4231.e8. PubMed ID: 36400008
[TBL] [Abstract][Full Text] [Related]
9. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
[TBL] [Abstract][Full Text] [Related]
10. POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.
Schrempf A; Bernardo S; Arasa Verge EA; Ramirez Otero MA; Wilson J; Kirchhofer D; Timelthaler G; Ambros AM; Kaya A; Wieder M; Ecker GF; Winter GE; Costanzo V; Loizou JI
Cell Rep; 2022 Nov; 41(9):111716. PubMed ID: 36400033
[TBL] [Abstract][Full Text] [Related]
11. 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice.
Chen J; Li P; Song L; Bai L; Huen MSY; Liu Y; Lu LY
Cell Death Differ; 2020 Sep; 27(9):2552-2567. PubMed ID: 32139898
[TBL] [Abstract][Full Text] [Related]
12. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation.
Isono M; Niimi A; Oike T; Hagiwara Y; Sato H; Sekine R; Yoshida Y; Isobe SY; Obuse C; Nishi R; Petricci E; Nakada S; Nakano T; Shibata A
Cell Rep; 2017 Jan; 18(2):520-532. PubMed ID: 28076794
[TBL] [Abstract][Full Text] [Related]
14. POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis.
Llorens-Agost M; Ensminger M; Le HP; Gawai A; Liu J; Cruz-García A; Bhetawal S; Wood RD; Heyer WD; Löbrich M
Nat Cell Biol; 2021 Oct; 23(10):1095-1104. PubMed ID: 34616022
[TBL] [Abstract][Full Text] [Related]
15. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
[TBL] [Abstract][Full Text] [Related]
16. Replicated chromatin curtails 53BP1 recruitment in BRCA1-proficient and BRCA1-deficient cells.
Michelena J; Pellegrino S; Spegg V; Altmeyer M
Life Sci Alliance; 2021 Jun; 4(6):. PubMed ID: 33811064
[TBL] [Abstract][Full Text] [Related]
17. ZMYM2 restricts 53BP1 at DNA double-strand breaks to favor BRCA1 loading and homologous recombination.
Lee D; Apelt K; Lee SO; Chan HR; Luijsterburg MS; Leung JWC; Miller KM
Nucleic Acids Res; 2022 Apr; 50(7):3922-3943. PubMed ID: 35253893
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
19. RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
Lok BH; Carley AC; Tchang B; Powell SN
Oncogene; 2013 Jul; 32(30):3552-8. PubMed ID: 22964643
[TBL] [Abstract][Full Text] [Related]
20. RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1.
Muñoz MC; Laulier C; Gunn A; Cheng A; Robbiani DF; Nussenzweig A; Stark JM
J Biol Chem; 2012 Nov; 287(48):40618-28. PubMed ID: 23055523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
